Defunct Company
Total Trials
9
As Lead Sponsor
7
As Collaborator
2
Total Enrollment
1,206
NCT02612207
Point-of-Care System for Determination of Bilirubin Capacity in Neonates
Phase: N/A
Role: Collaborator
Start: Aug 1, 2015
Completion: Aug 31, 2018
NCT02033616
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 18, 2017
Completion: Mar 31, 2023
NCT03400917
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
Start: Jun 20, 2018
Completion: Feb 28, 2023
NCT04690387
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
Phase: Phase 1
Start: Dec 7, 2020
Completion: Jan 15, 2021
NCT04685603
Dendritic Cell Vaccine to Prevent COVID-19
Completion: Jan 31, 2022
NCT05007496
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
Start: Apr 14, 2021
Completion: May 31, 2021
NCT03743298
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
Start: Apr 21, 2021
Completion: May 31, 2026
NCT04386252
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults
Phase: Phase 1/2
Start: Jan 31, 2023
Completion: Jan 31, 2024
NCT05100641
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
Phase: Phase 3
Start: Jan 31, 2024
Completion: Mar 31, 2029